Skip to content
DataLookout
Menu

NCT06585410

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 25 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 9 words
    • Study sites: 52 to 53
  2. Notable Eligibility criteria expanded, about 11 wordsv25
  3. Minor Study sites revised (52)v24
  4. Minor Study sites: 50 to 52v23
  5. Notable Eligibility criteria expanded, about 3 words
    • Study sites: 49 to 50
    • Secondary endpoints revised (6)
    v22
Show 19 earlier versionsHide 19 earlier versions
  1. Minor Site details revised at 1 of 49 sitesv21
  2. Minor Study sites: 48 to 49v20
  3. Minor Site details revised at 1 of 48 sitesv19
  4. Minor Study sites: 47 to 48v18
  5. Minor Study sites: 45 to 47v17
  6. Minor Study sites: 41 to 45v16
  7. Minor Study sites: 40 to 41v15
  8. Minor Study sites: 39 to 40v14
  9. Minor Study sites: 30 to 39v13
  10. Minor Study sites revised (30)v12
  11. Minor Study sites: 29 to 30v11
  12. Minor Study sites: 27 to 29v10
  13. Minor Study sites: 23 to 27v9
  14. Minor Study sites: 20 to 23v8
  15. Minor Study sites: 18 to 20v6
  16. Minor Study sites: 12 to 18v5
  17. Minor Study sites: 5 to 12v4
  18. Minor Study sites: 4 to 5v3
  19. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jun 3, 2029 to May 3, 2030
    • Study sites: 0 to 4
    • Start date changed from estimate of Jan 28, 2025 to Jan 2, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Event-Free Survival (EFS) as assessed by the investigator
Timeframe: Up to 1 year
EFS as assessed by the investigator
Timeframe: Up to 3 years

Secondary (6)

Composite Complete Response (CCR) for Target Lesion (TL)
Non-Target Lesions (NTLs) in the Region of the Target Lesion (ROTL)
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Severity of TEAEs
Size of surgical defect
Show 1 moreShow less
Size of biopsy defect

Arms and interventions

Experimental ArmExperimental
Control ArmOther

Drugs: Cemiplimab

Procedures: Standard of care

Sites

53 sites in 2 countries

United States 48, Australia 5